P4HA1 and inflammatory bowel disease: Firstly, although we applied IHC to validate the expression levels of P4HA1 and PMM2 in patients with IBD and CRC, it lacks some clinical information, such as disease activity, previous therapies, and prognosis, which may have affected expression levels.